非肌层浸润性膀胱癌膀胱灌注治疗研究进展

锦强 李, 阳 薛, 昭群 郭, 沙舟 叶, 琪 马, 晓龙 贾 · 2026

Read 非肌层浸润性膀胱癌膀胱灌注治疗研究进展 by 锦强 李, 阳 薛, 昭群 郭, 沙舟 叶, 琪 马, 晓龙 贾 (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13500728.txt.

Description

锦强 李 and others review bladder instillation therapy for non-muscle-invasive bladder cancer, which accounts for about three quarters of new bladder cancer cases. In 2026, the Chinese-language review covers treatment after transurethral resection, where recurrence remains high and post-operative drug therapy is crucial. Options now span immune therapy, aimed therapy, antibody-drug conjugates, and novel giving systems.

Checkpoint blockers help high-risk patients who do not respond to BCG, while the conjugate RC-48 shows action in selected groups and erdafitinib targets FGFR-mutated tumours. New giving systems include a mitomycin hydrogel approved in the United States and sustained-release gemcitabine and erdafitinib devices. The review aims to guide evidence-based, personalized choices and combination plans.

Catalog record

CREATOR锦强 李, 阳 薛, 昭群 郭, 沙舟 叶, 琪 马, 晓龙 贾
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE27 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13500728

Browse the full library · About the Tower of Babel